Abstract:Background: Insurance coverage for fertility services may reduce the financial burden of high-cost fertility care such as assisted reproductive technology and improve its utilization. Patients who exit care after failing to reach their reproductive goals report higher rates of mental health problems and a lower sense of well-being. It is important to understand the relationship between state-mandated insurance coverage for fertility services and assisted reproductive technology care discontinuation. Objective: This study aimed to assess whether state-mandated insurance coverage for fertility services is associated with lower rates of care discontinuation after an initial assisted reproductive technology cycle that did not result in a live birth. Study design: This is a retrospective, population-based cohort study using data from United States fertility clinics reporting to the National Assisted Reproductive Technology Surveillance System during 2016 and 2018. Patients who began their first autologous assisted reproductive technology cycle during 2016 and 2017 and did not have a live birth were included. We describe the rate of assisted reproductive technology care discontinuation (no additional cycle within 12 months of the previous cycle's date of failure). Multivariable analyses were conducted to evaluate factors independently associated with care discontinuation, including the scope of fertility services included in state coverage mandate at assisted reproductive technology cycle initiation that were as follows: comprehensive (≥3 assisted reproductive technology cycles), limited (1, 2, or an unspecified number of assisted reproductive technology cycles), mandate not including assisted reproductive technology, and no mandate. Results: Among 91,324 patients who underwent their first autologous assisted reproductive technology cycle that did not result in live birth, 24,072 (26.4%) discontinued care. Compared with patients who lived in states with mandates for comprehensive assisted reproductive technology coverage, those in states with mandates for fertility services coverage that did not include assisted reproductive technology or states with no mandate were 46% (adjusted relative risk, 1.46; 95% confidence interval, 1.31-1.63) and 26% (adjusted relative risk, 1.26; 95% confidence interval, 1.15-1.39) more likely to discontinue care, respectively, after controlling for patient and cycle characteristics. Increasing patient age, distance from clinic ≥50 miles, previous live birth, fewer oocytes retrieved, and not having embryos cryopreserved were also associated with higher rates of discontinuation. Non-Hispanic Black, non-Hispanic Asian, and Hispanic patients had higher rates of care discontinuation than non-Hispanic White patients regardless of the existence or scope of state-mandated assisted reproductive technology coverage. Conclusion: Comprehensive state-mandated insurance coverage for assisted reproductive technology is associated with lower rates of assisted reproductive technology care discontinuation.

State-Mandated Insurance Coverage and Preimplantation Genetic Testing in the United States

Research Progress and Challenges of Preimplantation Genetic Testing for Polygenic Diseases.

Association of state insurance coverage mandates with assisted reproductive technology care discontinuation

Unequal Uptake: Insurance‐Related Disparities in Prenatal Genetic Counseling and Screening at a Quaternary Medical Center

Regulating Preimplantation Genetic Testing across the World: A Comparison of International Policy and Ethical Perspectives

Determinants of utilization of infertility services by race and ethnicity in a state with a comprehensive infertility mandate

Implementation of state health insurance benefit mandates for cancer-related fertility preservation: following policy through a complex system

The Status of Fertility Preservation (FP) Insurance Mandates and Their Impact on Utilization and Access to Care

"Comparison of Outcomes Between Intracytoplasmic Sperm Injection and In Vitro Fertilization with Pre-implantation Genetic Testing for Aneuploidy, Analysis of SART CORS Data".

Conflict between values and technology: perceptions of preimplantation genetic diagnosis among women at increased risk for hereditary breast and ovarian cancer

Preimplantation Genetic Testing for Polygenetic Conditions: A Legal, Ethical, and Scientific Challenge

The impact of preimplantation genetic testing for aneuploidy on prenatal screening

Preconception carrier screening and preimplantation genetic testing in the infertility management

Fertility care for all: impact of New York State's Medicaid expansion on infertility care

It’s More Than a Blood Test: Patients’ Perspectives on Noninvasive Prenatal Testing

Designing and implementing state-level fertility preservation health insurance benefit mandates

Noninvasive preimplantation genetic testing in assisted reproductive technology: current state and future perspectives

Preimplantation Genetic Testing Guidelines of International Society of Reproductive Genetics

Current Status and New Progress of the Preimplantation Genetic Testing

Preimplantation genetic testing: A remarkable history of pioneering, technical challenges, innovations, and ethical considerations

The Role of Race and Insurance Status in Access to Genetic Counseling and Testing Among High-Risk Breast Cancer Patients